How to grow bone to treat osteoporosis and mend fractures

Current Rheumatology Reports

Volumn 5, Issue 1, 2003, Pages 45-56

  Whitfield, James F ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Anabolic Agent; Human Parathyroid Hormone; Osteoblastic Cell; Parathyroid Hormone; Pitavastatin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; PARATHYROID HORMONE;

ANIMAL; ANIMAL MODEL; BONE; BONE DEVELOPMENT; BONE REGENERATION; CELL TRANSFORMATION; DRUG EFFECT; FRACTURE; HUMAN; OSTEOPOROSIS; PHYSIOLOGY; REVIEW;

ANIMALS; BONE AND BONES; BONE REGENERATION; CELL TRANSFORMATION, NEOPLASTIC; FRACTURES, BONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEPTIN; MODELS, ANIMAL; OSTEOGENESIS; OSTEOPOROSIS; PARATHYROID HORMONE;

EID: 0037946799     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-003-0083-8     Document Type: Article

References (71)

1. Seeman E, Delmas PD: Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrinol Metab 2001, 12:281–283. An exceptionally clear discussion of the difference between antiresorptives and bone anabolics. DOI: 10.1016/S1043-2760(01)00460-X
2. Boivin GY, Chavassieux PM, Santora AC, et al.: Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687–694. DOI: 10.1016/S8756-3282(00)00376-8
3. Martin RB: Is all cortical bone remodeling initiated by microdamage? Bone 2002, 30:8–13. This article presents the case for the activation of bone-remodeling BMUs being the response to microcracking. DOI: 10.1016/S8756-3282(01)00620-2
4. Bilezikian JP, Raisz LG, Rodan GA: Bone Biology, vol 1 and 2, edn 2. San Diego: Academic Press; 2002. The latest authoritative multiauthored compendium of information on bone biology.
5. Whitfield JF: The parathyroid hormones: anabolic tools for mending fractures and treating osteoporosis. Medscape Women’s Health Clinical Updates 2001. Available at: http:// www.medscape.com/Medscape/WomensHealth/ClincalUpdate/ 2001/v06.no5/wh01004.whit/wh01004. The most recent comprehensive and extensively referenced review of the PTHs and their osteogenicity.
6. Marotti G: The structure of bone tissues and the cellular control of their deposition. Ital J Anat Embyol 2003, 101:25–79. An explanation of how osteocytes and bone-lining cells interact to control bone remodeling and repair.
7. Hofbauer LC, Heufelder AE: Role of receptor activator of nuclear factor-kB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001, 79:243–253. DOI: 10.1007/s001090100226
8. Parikka V, Lehenkari P, Sassi ML, et al.: Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology 2001, 142:5371–5378. DOI: 10.1210/en.142.12.5371
9. Manolagas SC: Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrine Revs 2000, 21:115–137. DOI: 10.1210/er.21.2.115
10. Bilezekian JP, Marcus MA, Levine MA: The Parathyroid Hormone, edn 2. San Diego: Academic Press; 2001. The most recent multiauthored compendium of information and references on all aspects of PTH, its fragments, and receptors.
11. Whitfield JF, Morley P, Willick GE: The Parathyroid Hormone: An Unexpected Bone Builder for Treating Osteoporosis. Austin: Landes Bioscience; 1998. Published in late 1998, this is, so far, the only monograph dealing specifically with the events leading to the discovery and use of PTHs as anabolic agents for treating opsteoporosis. It is a source of references for reports published between 1929 and mid-1998.
12. Jouishomme H, Whitfield JF, Chakravarthy B, et al.: The protein kinase-C activation domain of the parathyroid hormone. Endocrinology 1992, 130:53–60. Although from 1992, this is the first article that located PTH’s PLC/ PKCs-activation domains. DOI: 10.1210/en.130.1.53
13. Rixon RH, Whitfield JF, Gognon L, et al.: Parathyroid hormone may stimulate bone growth in ovariectomized rats by activating adenyly cyclase. J Bone Miner Res 1994, 9:1179–1189. The first demonstration using OVX rats that PTH needs only to stimulate AC to trigger osteogenesis. DOI: 10.1002/jbmr.5650090807
14. Jerome CP, Burr DB, Van Bibber T, et al.: Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 2001, 28:150–159. DOI: 10.1016/S8756-3282(00)00430-0
15. Hodsman AB, Steer BM: Early histomorhometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 1993, 14:523–527. DOI: 10.1016/8756-3282(93)90190-L
16. Aubin JE, Triffitt JT: Mesenchymal stem cells and osteoblast differententiation. In Bone Biology, vol 1, edn 2. Edited by Bilezikian JP, Raisz LG, Rodan GA. San Diego: Academic Press; 2002:59–91. The most up-to-date discussion of osteoblastic cell differentiation and somatic mosaicism of bone cells.
17. Burr DB, Hirano T, Turner CH, et al.: Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16:157–165. DOI: 10.1359/jbmr.2001.16.1.157
18. Andreassen TT, Ejersted C, Oxlund H: Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing fractures. J Bone Miner Res 1999, 14:960–968. DOI: 10.1359/jbmr.1999.14.6.960
19. Kim HW, Jahng JS: Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. Iowa Orthop J 1999, 19:71–77.
20. Bonadio J: Tissue engineering via local gene delivery; update and future prospects for enhancing the technology. Adv Drug Del Rev 2000, 44:185–194. DOI: 10.1016/S0169-409X(00)00094-6
21. Mosekilde L, Reeve J: Treatment with PTH peptides. In Osteoporosis, vol 2, edn 2. Edited by Marcus R, Feldman D, Kelsey J. San Diego: Academic Press; 2001:725–746.
22. Fujita T, Inoue T, Morii H, et al.: Effect of intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteoporos Int 1999, 9:296–306. DOI: 10.1007/s001980050151
23. Roe EB, Sanchez SD, del Puerto GA, et al.: Parathyroid hormona 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in post-menopausal osteoporosis: results from a placebo-controlled randomized trial. J Bone Miner Res 1999, 14:S137.
24. Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000, 85:2129–2134. DOI: 10.1210/jc.85.6.2129
25. Kurland EH, Cosman F, McMahon DJ: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects of bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069–3076. DOI: 10.1210/jc.85.9.3069
26. Cann CE, Roe EB, Sanchez SD, et al.: PTH effects in the femur: envelope-specific responses by 3DQCT in postmenopausal women [abstract]. J Bone Miner Res 1999, 14:S137. Although it is only an abstract, this piece shows that the BMD drop in cortical bone during the 1st year of hPTH-(1-34) injections that has caused some concern is followed by dramatic increases in femoral endocortical and trabecular masses.
27. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441. This report contains the phase III trial data for Eli Lilly’s recombinant hPTH-(1-34) that were presented in July 2001 to the US Food and Drug Administration’s Center for Drug Evaluation and Research (Endocrinology and Metabolic Drugs Advisoiry Committee). On the recommendation of this panel, the US Food and Drug Administration approved the PTH fragment for treating men and women osteoporotics. DOI: 10.1056/NEJM200105103441904
28. Food and Drug Administration, Center for Drug Evaluation and Research: Endocrinologic and Metabolic Drugs Advisory Committee Meeting, July 27, 2001. Neal R Gross Court Reporters and Transcribers, 1323 Rhode Island Ave., NW, Washington DC 20005-3701. This transcript contains the full disclosure of the results of the human, monkey, and rat trials of Eli Lilly’s recombinant hPTH-(1-34) as a possible therapeutic for treating osteoporosis.
29. Raouf A, Seth A: Discovery of osteoblast-associated genes using cDNA microarrays. Bone 2002, 30:463–441. DOI: 10.1016/S8756-3282(01)00699-8
30. Whitfield JF, Morley P, Willick GE: The control of bone growth by parathyroid hormone (PTH), leptin and statins. Crit Rev Euk Gene Expr 2002, 12:23–51. DOI: 10.1615/CritRevEukaryotGeneExpr.v12.i1.20
31. Nakashima K, Zhou X, Kunkel G, et al.: The novel zinc-fingercontaining transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17–29. DOI: 10.1016/S0092-8674(01)00622-5
32. Thomas D, Cart SA, Piscopo DM, et al.: The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell 2001, 8:303–316. DOI: 10.1016/S1097-2765(01)00327-6
33. Lu SS, Ducayen-Knowles M, Dempster DW, et al.: Effects of parathyroid hormone on gene expression of RANK ligand (RANKL), osteoprotegerin (OPG) and the cognate receptor for PTH in mice. J Bone Miner Res 2001, 16:S426. DOI: 10.1359/jbmr.2001.16.5.901
34. Onyia JE, Gelbert I, Zhang M, et al.: Analysis of gene expression by actions of PTH in bone. J Bone Miner Res 2001, 16:S227.
35. Mehta N, Stern W, Sturmer A, et al.: Oral delivery of PTH analogs by a solid dosage formulation. J Bone Miner Res 2001, 16:S540. This is the first indication of how a PTH “pill” may be produced.
36. Mundy GR: Directions of drug discovery in osteoporosis. Ann Rev Med 2002, 53:337–354. DOI: 10.1146/annurev.med.53.082901.104047
37. Whitfield JF: Statins and the stimulation of bone growth: do they or don’t they? Geriatr Times 2002, 3:23–28.
38. Wang GJ, Chung KC, Shen WJ: Lipid-clearing agents in steroidinduced osteoporosis. J Formos Med Assoc 1995, 94:588–592.
39. Garrett IR, Gutierrez G, Mundy GR: Statins and bone formation. Curr Pharma Design 2001, 7:715–736. This is a review of the discovery of the statins’ osteogenicity from the view of the discoverers. DOI: 10.2174/1381612013397762
40. Crawford DT, Qi H, Chisey-Frink KL, et al.: Statin increases cortical bone in young male rats by single, local administration but fails to restore bone to ovariectomized (OVX) rats by daily systemic administration. J Bone Miner Res 2001, 16:S295.
41. Gasser J: Fluvastatin and cerivastatin are not anabolic for bone after local or systemic administration of non-toxic doses in mice and rats. J Bone Miner Res 2001, 16:S295.
42. Sato M, Schmidt A, Cole H, et al.: The skeletal efficacy of statins do not compare with low-dose parathyroid hormone. Bone 2001, 28:S80. DOI: 10.1016/S8756-3282(00)00414-2
43. Yao W, Li CY, Farmer RW, et al.: Simvastatin did not prevent bone loss in ovariectomized rats. J Bone Miner Res 2001, 16:S138.
44. LaCroix AZ, Cauley JA, Jackson R, et al.: Does statin use reduce the risk of fracture in postmenopausal women? Results from the Women’s Health Initiative Observational Study (WHIOS). J Bone Miner Res 2000, 15:S155. DOI: 10.1359/jbmr.2000.15.1.155
45. Sirola J, Honkanen R, Kruger H, et al.: Effects of HMG-CoA reductase inhibitors, statins, on bone loss: a prospective population-based cohort study in early post-menopausal women. Bone 2001, 28:S220. DOI: 10.1016/S8756-3282(00)00423-3
46. Cosman F, Nieves J, Zion M, et al.: Effects of short-term cerivastatin on bone turnover. J Bone Miner Res 2001, 16:S29. DOI: 10.1359/jbmr.2001.16.5.925
47. Feron O, Dessy C, Desager J-P, et al.: Hydroxy-methylglutarylcoenzyme Areductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001, 103:113–118.
48. Garrett IR, Gutierrez G, Chen D, et al.: Statins stimulate bone formation by enhancing eNOS expression. J Bone Miner Res 16:S75.
49. van’t Hof RJ, Ralston SH: Nitric oxide and bone. Immunology 2001, 103:255–261. DOI: 10.1046/j.1365-2567.2001.01261.x
50. Ohnaka K, Shimoda S, Nawata H, et al.: Pitavastatin-enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun 2001, 287:337–342. DOI: 10.1006/bbrc.2001.5597
51. Su LF, Knoblauch R, Garabedian MJ: Rho GTPases as modulators of the estrogen receptor transcriptional response. J Biol Chem 2001, 276:3231–3237. DOI: 10.1074/jbc.M005547200
52. Zhou S, Zilberman Y, Wassermann K, et al.: Estrogen modulates estrogen receptor a and b expression, osteogenic activity, and apoptosis in mesenchymal stem cells (MSCs) of osteoporotic mice. J Cell Biochem 2001, 36(suppl):144–155. DOI: 10.1002/jcb.1096
53. Ahima RS, Flier JS: Leptin. Ann Rev Physiol 2000, 62:413–437. DOI: 10.1146/annurev.physiol.62.1.413
54. Chu SC, Chou YC, Liu JY, et al.: Fluctuations of serum leptin levels in rats after ovariectomey and the influence of estrogen supplementation. Life Sci 1999, 64:2299–22306. DOI: 10.1016/S0024-3205(99)00181-2
55. Ducy P, Amling M, Takeda S, et al.: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197–207. The discovery of an osteoblast-restraining control mechanism in the brains of mice and rats. DOI: 10.1016/S0092-8674(00)81558-5
56. Whitfield JF: Leptin brains and bones. Exp Opin Invest Drugs 2001, 10:1617–1622. DOI: 10.1517/13543784.10.9.1617
57. Steppan CM, Crawford DT, Chidsey-Frink KI, et al.: Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000, 92:73–78. This report appears to flatly contradict the Ducy et al. [55••] demonstration of leptin’s anti-osteogenic action. DOI: 10.1016/S0167-0115(00)00152-X
58. Liu C, Grossman A, Bain S: Leptin stimulates cortical bone formation in obese mice. J Bone Miner Res 1997, 12:S115. DOI: 10.1359/jbmr.1997.12.10.1691
59. Maor GA, Rochwerger M, Segev Y, et al.: Leptin acts as a skeletal growth factor on chondrocytes of skeletal growth centers. J Bone Miner Res 2002, 17:1034–1043. DOI: 10.1359/jbmr.2002.17.6.1034
60. Cornish J, Callon KE, Bava U, et al.: The direct action of leptin on bone cells increase bone strength in vivo: an explanation of low fracture rates in obesity. Bone 2001, 28:S88.
61. Kume K, Satomura K, Nishisho S, et al.: Potential role of leptin in endochondral ossification. J Histochem Cytochem 2002, 50:159–169.
62. Evans BAJ, Elford C, Gregory JW: Leptin control of bone metabolism. Bone 2001, 28:S149.
63. Lee YJ, Park JH, Ko JS, et al.: Expression of signal transducing leptin receptors on rat osteoblasts indicates a direct involvement of leptin in the regulation of bone formation. J Bone Miner Res 2001, 16:S495.
64. Thomas T, De Vittoris R, David VN, et al.: Leptin prevents disuse- induced bone loss in tail-suspended female rats. J Bone Miner Res 2001, 16:S143.
65. Burguera B, Hofbauer LC, Thomas T, et al.: Leptin reduces ovariectomy- induced bone loss in rats. Endocrinology 2001, 142:3546–3553. DOI: 10.1210/en.142.8.3546
66. Bassilana F, Susa M, Keller HJ, et al.: Human mesechymal cells undergoing osteogenic differentiation express leptin and functional leptin receptors. J Bone Miner Res 2000, 15:S378.
67. Enjuanes A, Supervia A, Nogus X, et al.: Leptin receptor (OB-R) gene expression in human primary osteoblasts: confirmation [letter]. J Bone Miner Res 2002, 17:1135. DOI: 10.1359/jbmr.2002.17.6.1135
68. Gordeladze JO, Drevon CA, Syversen U, et al.: Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineraliztion: Impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 2002, 85:825–836. DOI: 10.1002/jcb.10156
69. Thomas T, Gori F, Khosla S, et al.: Leptin acts on human marrow stromal cells to enhance differentiation and to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999, 140:1630–1638. DOI: 10.1210/en.140.4.1630
70. Holloway WR, Collier FM, Aitken CJ, et al.: Leptin inhibits osteoclast generation. J Bone Miner Res 2002, 17:200–209. DOI: 10.1359/jbmr.2002.17.2.200
71. Baldock PA, Sainsbury A, Couzens M, et al.: Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002, 109:915–921. DOI: 10.1172/JCI200214588